Hims & Hers Retreats from Wegovy Copycat: What It Means for the Future of Weight-Loss Drugs
Novo Nordisk shares surged Monday after Hims & Hers announced it would discontinue sales of its cheaper, compounded version of the weight-loss pill Wegovy. The move comes after threats of legal action from Novo Nordisk and scrutiny from the U.S. Food and Drug Administration (FDA).
The Rise and Fall of the $49 Wegovy
Hims & Hers initially launched the compounded semaglutide pill for $49, significantly undercutting Novo Nordisk’s price of $149 for the branded Wegovy pill. This aggressive pricing strategy initially boosted Hims’ stock, but quickly drew the ire of Novo Nordisk, which vowed to take legal action, calling the product “an unapproved, inauthentic, and untested knockoff.”
The announcement of the cheaper copycat also sent ripples through the stock market, initially causing shares of both Novo Nordisk and Eli Lilly to decline. Though, Novo Nordisk shares rebounded after Hims’ decision to pull the product.
Regulatory Pressure and Patient Safety Concerns
The FDA also weighed in, stating its intention to take “decisive steps” to restrict compounding pharmacies like Hims from offering unapproved versions of GLP-1 drugs. The FDA’s concerns center around ensuring the quality, safety, and efficacy of these medications, as compounded drugs are not subject to the same rigorous testing and approval processes as branded pharmaceuticals.
Novo Nordisk emphasized that Hims’ actions constituted “illegal mass compounding” and posed a “significant risk to patient safety.” The company also highlighted Hims’ history of offering “knock-off GLP-1 products” and deceptive advertising.
The Compounding Loophole and its Future
Hims & Hers had been capitalizing on a regulatory loophole that allows companies to sell compounded versions of drugs when branded medications are in short supply. However, Novo Nordisk has since increased its manufacturing capacity, resolving previous supply constraints for both Wegovy and Ozempic. This shift in supply dynamics contributed to the FDA’s increased scrutiny of compounding pharmacies.
The FDA specifically noted that promotional materials for compounded drugs cannot claim they are generic versions or equivalent to FDA-approved medications.
Impact on Novo Nordisk and the GLP-1 Market
Novo Nordisk has cited compounding as a challenge to its U.S. Market performance and a factor contributing to its projected revenue and profit decline of 5% to 13% in 2026. The company’s CEO, Mike Doustdar, reported that 170,000 people were already taking Wegovy in early January.
The situation highlights the growing competition in the GLP-1 market, with Eli Lilly also emerging as a major player. The demand for these drugs, which have shown dramatic success in weight loss, continues to surge, creating both opportunities and challenges for pharmaceutical companies and regulators.
What’s Next for Weight-Loss Medication?
The Hims & Hers situation signals a potential tightening of regulations around compounded GLP-1 drugs. This could lead to:
- Increased Enforcement: The FDA is likely to increase its enforcement actions against compounding pharmacies that violate regulations.
- Higher Prices: With the crackdown on cheaper copycats, the price of GLP-1 medications may remain relatively high, potentially limiting access for some patients.
- Focus on Innovation: Pharmaceutical companies will likely continue to invest in research and development to create new and improved weight-loss medications.
FAQ
Q: What is semaglutide?
A: Semaglutide is the active ingredient in Wegovy and Ozempic, medications used for weight loss and diabetes management.
Q: What is compounding?
A: Compounding is the practice of creating customized medications by combining or altering ingredients.
Q: Why did Hims & Hers stop selling the Wegovy copycat?
A: Hims & Hers stopped selling the copycat due to threats of legal action from Novo Nordisk and increased scrutiny from the FDA.
Q: Will the price of Wegovy go down?
A: It’s uncertain whether the price of Wegovy will decrease. The removal of the cheaper copycat may maintain current pricing levels.
Did you know? Novo Nordisk acquired fill-finish manufacturer Catalent for $16.5 billion to expand Wegovy supply.
Pro Tip: Always consult with a healthcare professional before starting any new medication, including weight-loss drugs.
Stay informed about the latest developments in the pharmaceutical industry. Explore more healthcare news on CNBC.
